Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases

dc.contributor.author
Torrent, Joan
dc.contributor.author
Vílchez Acosta, Alba del Valle
dc.contributor.author
Muñoz-Torrero López-Ibarra, Diego
dc.contributor.author
Trovaslet, M.
dc.contributor.author
Nachon, Florian
dc.contributor.author
Chatonnet, A.
dc.contributor.author
Grznarova, K.
dc.contributor.author
Acquatella-Tran Van Ba, I.
dc.contributor.author
Goffic, R. Le
dc.contributor.author
Herzog, Laetitia
dc.contributor.author
Béringue, V.
dc.contributor.author
Rezaei, H.
dc.date.issued
2015-09-02T11:42:27Z
dc.date.issued
2015-09-02T11:42:27Z
dc.date.issued
2015-04-03
dc.date.issued
2015-09-02T11:42:28Z
dc.identifier
2051-5960
dc.identifier
https://hdl.handle.net/2445/66823
dc.identifier
648300
dc.identifier
25853328
dc.description.abstract
The prion protein (PrP) binds to various molecular partners, but little is known about their potential impact on the pathogenesis of prion diseases. Here, we show that PrP can interact in vitro with acetylcholinesterase (AChE), a key protein of the cholinergic system in neural and non-neural tissues. This heterologous association induced aggregation of monomeric PrP and modified the structural properties of PrP amyloid fibrils. Following its recruitment into PrP fibrils, AChE loses its enzymatic activity and enhances PrP-mediated cytotoxicity. Using several truncated PrP variants and specific tight-binding AChE inhibitors (AChEis), we then demonstrate that the PrP-AChE interaction requires two mutually exclusive sub-sites in PrP N-terminal domain and an aromatic-rich region at the entrance of AChE active center gorge. We show that AChEis that target this site impair PrP-AChE complex formation and also limit the accumulation of pathological prion protein (PrPSc) in prion-infected cell cultures. Furthermore, reduction of AChE levels in prion-infected heterozygous AChE knock-out mice leads to slightly but significantly prolonged incubation time. Finally, we found that AChE levels were altered in prion-infected cells and tissues, suggesting that AChE might be directly associated with abnormal PrP. Our results indicate that AChE deserves consideration as a new actor in expanding pathologically relevant PrP morphotypes and as a therapeutic target.
dc.format
18 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a: http://dx.doi.org/10.1186/s40478-015-0188-0
dc.relation
Acta Neuropathologica Communications, 2015, vol. 3, num. 18
dc.relation
http://dx.doi.org/10.1186/s40478-015-0188-0
dc.rights
cc-by (c) Torrent et al., 2015
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Amiloïdosi
dc.subject
Malalties neurodegeneratives
dc.subject
Proteïnes
dc.subject
Amyloidosis
dc.subject
Neurodegenerative Diseases
dc.subject
Proteins
dc.title
Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)